Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Nodule | 52 | 2023 | 760 | 5.760 |
Why?
|
Biopsy, Fine-Needle | 54 | 2023 | 1111 | 5.090 |
Why?
|
Thyroid Neoplasms | 56 | 2023 | 2332 | 4.060 |
Why?
|
Vaginal Smears | 33 | 2021 | 495 | 3.790 |
Why?
|
Thyroid Gland | 31 | 2021 | 1169 | 3.600 |
Why?
|
Cytodiagnosis | 26 | 2022 | 432 | 3.300 |
Why?
|
Adenocarcinoma, Follicular | 17 | 2023 | 325 | 2.270 |
Why?
|
Cervix Uteri | 15 | 2021 | 585 | 1.990 |
Why?
|
Cytological Techniques | 11 | 2021 | 218 | 1.900 |
Why?
|
Uterine Cervical Dysplasia | 17 | 2015 | 387 | 1.860 |
Why?
|
Uterine Cervical Neoplasms | 27 | 2015 | 2018 | 1.780 |
Why?
|
Pleural Effusion, Malignant | 8 | 2018 | 103 | 1.530 |
Why?
|
Biopsy, Needle | 23 | 2017 | 1633 | 0.940 |
Why?
|
Ascitic Fluid | 5 | 2018 | 189 | 0.890 |
Why?
|
Cytogenetics | 3 | 2013 | 198 | 0.840 |
Why?
|
Carcinoma, Papillary | 14 | 2018 | 785 | 0.790 |
Why?
|
Mesothelioma | 11 | 2014 | 806 | 0.780 |
Why?
|
Cell Biology | 2 | 2021 | 90 | 0.740 |
Why?
|
Carcinoma | 14 | 2018 | 2334 | 0.660 |
Why?
|
Pathology, Clinical | 3 | 2017 | 375 | 0.640 |
Why?
|
False Negative Reactions | 12 | 2020 | 574 | 0.640 |
Why?
|
Professional Competence | 2 | 2017 | 431 | 0.600 |
Why?
|
Carcinoma, Squamous Cell | 8 | 2018 | 4024 | 0.580 |
Why?
|
Papillomavirus Infections | 7 | 2015 | 1600 | 0.560 |
Why?
|
Research Report | 1 | 2020 | 370 | 0.560 |
Why?
|
Endometrium | 3 | 2006 | 403 | 0.550 |
Why?
|
Pleural Neoplasms | 7 | 2009 | 609 | 0.540 |
Why?
|
Pericardial Effusion | 1 | 2018 | 247 | 0.530 |
Why?
|
In Situ Hybridization, Fluorescence | 7 | 2013 | 2500 | 0.530 |
Why?
|
Quality Control | 7 | 2010 | 827 | 0.530 |
Why?
|
Papillomaviridae | 7 | 2009 | 1117 | 0.490 |
Why?
|
Keratins | 5 | 2018 | 497 | 0.480 |
Why?
|
Pathology, Surgical | 3 | 2010 | 151 | 0.460 |
Why?
|
Ultrasonography | 21 | 2023 | 5960 | 0.440 |
Why?
|
Thyroidectomy | 9 | 2020 | 903 | 0.430 |
Why?
|
Terminology as Topic | 7 | 2021 | 1534 | 0.430 |
Why?
|
Observer Variation | 7 | 2013 | 2596 | 0.420 |
Why?
|
Immunohistochemistry | 15 | 2018 | 11064 | 0.410 |
Why?
|
Glucose Transporter Type 1 | 2 | 2011 | 186 | 0.410 |
Why?
|
Rhabdoid Tumor | 1 | 2014 | 210 | 0.400 |
Why?
|
Sensitivity and Specificity | 32 | 2019 | 14656 | 0.400 |
Why?
|
Diagnosis, Differential | 26 | 2017 | 12968 | 0.400 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2019 | 938 | 0.400 |
Why?
|
Humans | 189 | 2023 | 760261 | 0.390 |
Why?
|
Genital Neoplasms, Female | 1 | 2017 | 538 | 0.390 |
Why?
|
Thyroid Diseases | 3 | 2010 | 386 | 0.380 |
Why?
|
Teratoma | 1 | 2014 | 403 | 0.380 |
Why?
|
STAT3 Transcription Factor | 1 | 2015 | 877 | 0.380 |
Why?
|
Adenocarcinoma | 12 | 2016 | 6310 | 0.370 |
Why?
|
Oxyphil Cells | 1 | 2011 | 57 | 0.360 |
Why?
|
Abdominal Neoplasms | 3 | 2008 | 286 | 0.360 |
Why?
|
Cell Nucleus | 5 | 2017 | 2909 | 0.360 |
Why?
|
Kidney Diseases | 4 | 2007 | 2093 | 0.350 |
Why?
|
Classification | 1 | 2010 | 127 | 0.350 |
Why?
|
Specimen Handling | 5 | 2019 | 708 | 0.350 |
Why?
|
Quality Assurance, Health Care | 5 | 2017 | 2178 | 0.350 |
Why?
|
Female | 127 | 2023 | 391011 | 0.340 |
Why?
|
Hashimoto Disease | 1 | 2011 | 105 | 0.340 |
Why?
|
Chromosome Aberrations | 5 | 2013 | 1767 | 0.330 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2009 | 60 | 0.330 |
Why?
|
Pathology, Molecular | 1 | 2012 | 330 | 0.320 |
Why?
|
Mucin-1 | 3 | 2011 | 539 | 0.310 |
Why?
|
Flow Cytometry | 9 | 2013 | 5873 | 0.310 |
Why?
|
Carcinoma, Papillary, Follicular | 2 | 2018 | 60 | 0.300 |
Why?
|
Kidney Neoplasms | 6 | 2010 | 4312 | 0.290 |
Why?
|
Meningeal Carcinomatosis | 2 | 2019 | 63 | 0.290 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2008 | 124 | 0.290 |
Why?
|
Tumor Virus Infections | 3 | 2008 | 438 | 0.290 |
Why?
|
Nuclear Proteins | 2 | 2014 | 5793 | 0.280 |
Why?
|
Antigens, Neoplasm | 2 | 2008 | 1999 | 0.280 |
Why?
|
Retrospective Studies | 42 | 2023 | 80301 | 0.270 |
Why?
|
Needles | 3 | 2008 | 451 | 0.270 |
Why?
|
Adult | 72 | 2022 | 219847 | 0.260 |
Why?
|
Quality Improvement | 1 | 2021 | 3840 | 0.260 |
Why?
|
Task Performance and Analysis | 2 | 2008 | 759 | 0.260 |
Why?
|
DNA, Neoplasm | 7 | 2017 | 1745 | 0.250 |
Why?
|
Ependymoma | 1 | 2008 | 320 | 0.250 |
Why?
|
Middle Aged | 75 | 2019 | 220175 | 0.250 |
Why?
|
Endometrial Neoplasms | 1 | 2014 | 1361 | 0.250 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 698 | 0.250 |
Why?
|
Biopsy | 6 | 2013 | 6775 | 0.240 |
Why?
|
Carcinoma in Situ | 4 | 1999 | 796 | 0.240 |
Why?
|
Aged, 80 and over | 30 | 2019 | 58947 | 0.230 |
Why?
|
Brain Neoplasms | 4 | 2014 | 8984 | 0.230 |
Why?
|
Mullerian Ducts | 1 | 2005 | 201 | 0.230 |
Why?
|
Cerebrospinal Fluid | 5 | 2016 | 544 | 0.230 |
Why?
|
Perimenopause | 1 | 2005 | 141 | 0.230 |
Why?
|
Aged | 57 | 2019 | 168995 | 0.230 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2023 | 89 | 0.220 |
Why?
|
Male | 83 | 2023 | 359413 | 0.210 |
Why?
|
Stromal Cells | 2 | 2006 | 1327 | 0.210 |
Why?
|
Gene Expression Profiling | 6 | 2020 | 9388 | 0.210 |
Why?
|
Reproducibility of Results | 16 | 2017 | 20048 | 0.200 |
Why?
|
Neoplasm Proteins | 4 | 2015 | 3613 | 0.200 |
Why?
|
Prognosis | 15 | 2018 | 29636 | 0.200 |
Why?
|
Neoplasms | 8 | 2023 | 22066 | 0.200 |
Why?
|
Lymphoproliferative Disorders | 3 | 2014 | 533 | 0.200 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2011 | 2823 | 0.200 |
Why?
|
Nasal Mucosa | 2 | 2015 | 413 | 0.190 |
Why?
|
Pleural Effusion | 3 | 1997 | 343 | 0.190 |
Why?
|
Predictive Value of Tests | 15 | 2017 | 15273 | 0.180 |
Why?
|
Uterine Cervical Diseases | 1 | 2001 | 74 | 0.180 |
Why?
|
Toxoplasmosis | 1 | 2000 | 93 | 0.180 |
Why?
|
Diagnosis | 1 | 2021 | 157 | 0.170 |
Why?
|
DNA, Viral | 1 | 2006 | 2195 | 0.170 |
Why?
|
Toxoplasma | 1 | 2000 | 151 | 0.170 |
Why?
|
Laboratories, Hospital | 1 | 2001 | 193 | 0.170 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2019 | 66 | 0.160 |
Why?
|
Angiomyolipoma | 1 | 2001 | 184 | 0.160 |
Why?
|
Astrocytoma | 1 | 2004 | 775 | 0.160 |
Why?
|
Eosinophilia | 1 | 2023 | 560 | 0.160 |
Why?
|
Parotid Diseases | 1 | 1999 | 49 | 0.160 |
Why?
|
Epithelial Cells | 2 | 2015 | 3665 | 0.160 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2008 | 1890 | 0.160 |
Why?
|
ROC Curve | 3 | 2008 | 3568 | 0.160 |
Why?
|
False Positive Reactions | 2 | 2020 | 956 | 0.150 |
Why?
|
Follow-Up Studies | 13 | 2023 | 39254 | 0.150 |
Why?
|
SOXE Transcription Factors | 1 | 2018 | 73 | 0.150 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2015 | 612 | 0.150 |
Why?
|
Parotid Gland | 1 | 1999 | 175 | 0.150 |
Why?
|
Cytoplasm | 3 | 2008 | 1518 | 0.150 |
Why?
|
Entosis | 2 | 2014 | 6 | 0.150 |
Why?
|
Lung Neoplasms | 8 | 2019 | 13249 | 0.150 |
Why?
|
Leiomyosarcoma | 1 | 2001 | 424 | 0.140 |
Why?
|
Liposarcoma | 2 | 2013 | 283 | 0.140 |
Why?
|
Ureteral Diseases | 1 | 1997 | 65 | 0.140 |
Why?
|
Retroperitoneal Fibrosis | 1 | 1997 | 41 | 0.140 |
Why?
|
Young Adult | 16 | 2022 | 58673 | 0.140 |
Why?
|
Cell Cycle Proteins | 1 | 2008 | 3448 | 0.140 |
Why?
|
Transcription Factors | 2 | 2014 | 12100 | 0.140 |
Why?
|
Image Enhancement | 1 | 2007 | 2877 | 0.140 |
Why?
|
Antigens, Surface | 1 | 2001 | 1616 | 0.140 |
Why?
|
Mass Screening | 5 | 2010 | 5422 | 0.130 |
Why?
|
Sentinel Surveillance | 1 | 2018 | 293 | 0.130 |
Why?
|
Practice Guidelines as Topic | 8 | 2018 | 7468 | 0.130 |
Why?
|
DNA-Binding Proteins | 2 | 2014 | 9590 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2019 | 8498 | 0.130 |
Why?
|
Speech Disorders | 1 | 2016 | 180 | 0.130 |
Why?
|
Adolescent | 24 | 2019 | 87747 | 0.130 |
Why?
|
Epithelium | 3 | 2014 | 1605 | 0.120 |
Why?
|
Pelvic Neoplasms | 2 | 2010 | 248 | 0.120 |
Why?
|
Hyperthyroidism | 1 | 1997 | 291 | 0.120 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2019 | 421 | 0.120 |
Why?
|
Diagnostic Errors | 4 | 2016 | 1266 | 0.120 |
Why?
|
Iodine Radioisotopes | 2 | 2002 | 1032 | 0.120 |
Why?
|
Immunophenotyping | 3 | 2013 | 1870 | 0.120 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 3 | 2017 | 1729 | 0.120 |
Why?
|
Cysts | 4 | 2005 | 683 | 0.120 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2018 | 586 | 0.110 |
Why?
|
Neoplasm Staging | 7 | 2017 | 11141 | 0.110 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2001 | 951 | 0.110 |
Why?
|
WT1 Proteins | 1 | 2014 | 184 | 0.110 |
Why?
|
Hyperplasia | 2 | 2014 | 1158 | 0.110 |
Why?
|
Adenoma | 2 | 2017 | 2148 | 0.110 |
Why?
|
Aneuploidy | 5 | 2011 | 551 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1997 | 549 | 0.100 |
Why?
|
Gene Expression | 3 | 2019 | 7592 | 0.100 |
Why?
|
Cadherins | 2 | 2014 | 898 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2019 | 1094 | 0.100 |
Why?
|
Risk | 5 | 2019 | 9629 | 0.100 |
Why?
|
Child, Preschool | 10 | 2019 | 42034 | 0.100 |
Why?
|
Neoplasm Invasiveness | 5 | 2017 | 3618 | 0.100 |
Why?
|
Desmin | 1 | 2011 | 99 | 0.100 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2013 | 169 | 0.100 |
Why?
|
Histiocytoma, Malignant Fibrous | 1 | 2011 | 55 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 368 | 0.090 |
Why?
|
Preoperative Period | 1 | 2013 | 555 | 0.090 |
Why?
|
Radiology, Interventional | 2 | 2011 | 475 | 0.090 |
Why?
|
Radiography | 5 | 2016 | 6965 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2007 | 729 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 5248 | 0.090 |
Why?
|
Medical Errors | 1 | 2019 | 1255 | 0.090 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2010 | 295 | 0.090 |
Why?
|
Cohort Studies | 12 | 2019 | 41317 | 0.090 |
Why?
|
Child | 14 | 2022 | 79758 | 0.090 |
Why?
|
Immunomagnetic Separation | 1 | 2010 | 79 | 0.090 |
Why?
|
Lasers | 1 | 1994 | 952 | 0.090 |
Why?
|
Disease Susceptibility | 1 | 1997 | 1791 | 0.090 |
Why?
|
Adrenal Cortex | 1 | 1990 | 134 | 0.090 |
Why?
|
DNA Mutational Analysis | 5 | 2018 | 4109 | 0.090 |
Why?
|
Kidney | 2 | 1997 | 7072 | 0.090 |
Why?
|
Palpation | 2 | 2008 | 166 | 0.090 |
Why?
|
Karyotyping | 3 | 2009 | 1172 | 0.090 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2013 | 556 | 0.090 |
Why?
|
Genes, erbB-2 | 1 | 2010 | 163 | 0.080 |
Why?
|
Peritoneum | 1 | 2010 | 225 | 0.080 |
Why?
|
Postoperative Period | 3 | 2013 | 1821 | 0.080 |
Why?
|
Age Factors | 5 | 2019 | 18415 | 0.080 |
Why?
|
Adenoma, Oxyphilic | 1 | 2011 | 148 | 0.080 |
Why?
|
Vagina | 1 | 1995 | 842 | 0.080 |
Why?
|
Alphapapillomavirus | 1 | 2012 | 218 | 0.080 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 1990 | 160 | 0.080 |
Why?
|
Nucleic Acid Hybridization | 1 | 2010 | 1304 | 0.080 |
Why?
|
Allied Health Personnel | 1 | 2010 | 156 | 0.080 |
Why?
|
DNA | 2 | 1995 | 7236 | 0.080 |
Why?
|
Arachnoid | 1 | 1987 | 50 | 0.080 |
Why?
|
Omentum | 1 | 2009 | 169 | 0.080 |
Why?
|
Consensus | 1 | 2017 | 3106 | 0.070 |
Why?
|
Confidence Intervals | 2 | 2011 | 2932 | 0.070 |
Why?
|
Melanoma | 2 | 2018 | 5695 | 0.070 |
Why?
|
Pia Mater | 1 | 1987 | 87 | 0.070 |
Why?
|
Metaplasia | 1 | 2008 | 320 | 0.070 |
Why?
|
Lung | 3 | 2016 | 9989 | 0.070 |
Why?
|
Hodgkin Disease | 2 | 1994 | 1381 | 0.070 |
Why?
|
Tumor Burden | 3 | 2019 | 1897 | 0.070 |
Why?
|
Peritoneal Neoplasms | 2 | 2009 | 706 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 6 | 2007 | 20484 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2014 | 1060 | 0.070 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2016 | 2052 | 0.070 |
Why?
|
Mitosis | 2 | 2011 | 1193 | 0.070 |
Why?
|
Feasibility Studies | 4 | 2014 | 5201 | 0.070 |
Why?
|
Endometriosis | 1 | 2014 | 871 | 0.070 |
Why?
|
Mutation | 6 | 2023 | 29950 | 0.070 |
Why?
|
Inclusion Bodies | 2 | 2004 | 281 | 0.070 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2010 | 475 | 0.070 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 4717 | 0.070 |
Why?
|
Immunocompromised Host | 2 | 2002 | 857 | 0.070 |
Why?
|
Prospective Studies | 10 | 2017 | 54263 | 0.060 |
Why?
|
Endocrine Glands | 1 | 2006 | 101 | 0.060 |
Why?
|
Infant | 5 | 2019 | 36030 | 0.060 |
Why?
|
Risk Assessment | 6 | 2019 | 24086 | 0.060 |
Why?
|
Diethylstilbestrol | 1 | 2005 | 88 | 0.060 |
Why?
|
Endometrial Hyperplasia | 1 | 2005 | 98 | 0.060 |
Why?
|
Lymphatic Metastasis | 3 | 2017 | 2945 | 0.060 |
Why?
|
PPAR gamma | 1 | 2008 | 484 | 0.060 |
Why?
|
Area Under Curve | 1 | 2009 | 1635 | 0.060 |
Why?
|
Thyrotropin | 1 | 2008 | 832 | 0.060 |
Why?
|
Uveitis, Anterior | 1 | 2005 | 102 | 0.060 |
Why?
|
Anterior Chamber | 1 | 2005 | 194 | 0.060 |
Why?
|
Stomach Neoplasms | 1 | 2014 | 1423 | 0.060 |
Why?
|
Immunoglobulins | 1 | 1987 | 863 | 0.060 |
Why?
|
Interdisciplinary Communication | 1 | 2010 | 934 | 0.060 |
Why?
|
Receptor, erbB-2 | 1 | 2014 | 2544 | 0.060 |
Why?
|
Menstruation | 1 | 2006 | 307 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 3 | 1999 | 8945 | 0.060 |
Why?
|
Neoplasm Metastasis | 4 | 2015 | 4891 | 0.060 |
Why?
|
Genotype | 1 | 2018 | 12959 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2023 | 3618 | 0.050 |
Why?
|
Atrophy | 1 | 2008 | 1625 | 0.050 |
Why?
|
Eye Neoplasms | 1 | 2005 | 306 | 0.050 |
Why?
|
Carcinoma, Transitional Cell | 4 | 1995 | 800 | 0.050 |
Why?
|
Neprilysin | 1 | 2006 | 472 | 0.050 |
Why?
|
Databases, Factual | 3 | 2015 | 8018 | 0.050 |
Why?
|
GTP Phosphohydrolases | 2 | 2017 | 516 | 0.050 |
Why?
|
Cooperative Behavior | 1 | 2010 | 1500 | 0.050 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2003 | 231 | 0.050 |
Why?
|
Employee Discipline | 1 | 2001 | 8 | 0.050 |
Why?
|
Informed Consent | 1 | 2008 | 1007 | 0.050 |
Why?
|
Premenopause | 1 | 2005 | 1039 | 0.050 |
Why?
|
Thoracic Wall | 1 | 2003 | 199 | 0.050 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2007 | 615 | 0.050 |
Why?
|
Hospitals, Teaching | 2 | 2016 | 1166 | 0.050 |
Why?
|
Melanoma-Specific Antigens | 1 | 2001 | 74 | 0.050 |
Why?
|
Thoracic Neoplasms | 1 | 2003 | 265 | 0.050 |
Why?
|
Precancerous Conditions | 1 | 2008 | 978 | 0.050 |
Why?
|
Hemangiosarcoma | 1 | 2003 | 218 | 0.050 |
Why?
|
Surgery, Computer-Assisted | 1 | 2009 | 1007 | 0.050 |
Why?
|
Cilia | 1 | 2005 | 492 | 0.050 |
Why?
|
Boston | 3 | 2016 | 9282 | 0.050 |
Why?
|
Cell Communication | 1 | 2007 | 1642 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2010 | 2927 | 0.040 |
Why?
|
Nuclear Matrix | 1 | 1999 | 30 | 0.040 |
Why?
|
rho-Associated Kinases | 2 | 2014 | 281 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 1 | 2007 | 36247 | 0.040 |
Why?
|
Urinary Bladder Neoplasms | 5 | 1995 | 2277 | 0.040 |
Why?
|
Autophagy | 1 | 2007 | 1336 | 0.040 |
Why?
|
Genomics | 1 | 2015 | 5790 | 0.040 |
Why?
|
Colposcopy | 1 | 1999 | 150 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2015 | 9274 | 0.040 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1999 | 761 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 854 | 0.040 |
Why?
|
Meningeal Neoplasms | 1 | 1987 | 1248 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1723 | 0.040 |
Why?
|
Lymphoma | 1 | 1987 | 1899 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5797 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2015 | 6067 | 0.040 |
Why?
|
Crystallization | 1 | 1999 | 533 | 0.040 |
Why?
|
Opportunistic Infections | 1 | 2000 | 377 | 0.040 |
Why?
|
Bile Ducts | 1 | 1999 | 282 | 0.040 |
Why?
|
Feedback | 1 | 2001 | 791 | 0.040 |
Why?
|
Histocytochemistry | 2 | 2010 | 693 | 0.040 |
Why?
|
Diagnostic Imaging | 2 | 2010 | 3526 | 0.040 |
Why?
|
Brain | 2 | 2004 | 26912 | 0.040 |
Why?
|
Pancreatic Ducts | 1 | 1999 | 329 | 0.040 |
Why?
|
Limit of Detection | 1 | 2018 | 280 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2010 | 3598 | 0.030 |
Why?
|
Papilloma | 2 | 1987 | 141 | 0.030 |
Why?
|
Color | 1 | 2018 | 298 | 0.030 |
Why?
|
Postmenopause | 1 | 2005 | 2503 | 0.030 |
Why?
|
Acid Phosphatase | 1 | 1996 | 139 | 0.030 |
Why?
|
Therapeutic Irrigation | 2 | 1995 | 292 | 0.030 |
Why?
|
Urine | 2 | 1987 | 363 | 0.030 |
Why?
|
Astrocytes | 1 | 2004 | 1335 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 2 | 2004 | 3217 | 0.030 |
Why?
|
Cholestasis | 1 | 1999 | 374 | 0.030 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 1539 | 0.030 |
Why?
|
Patient Selection | 2 | 2018 | 4276 | 0.030 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2002 | 608 | 0.030 |
Why?
|
Radiography, Interventional | 2 | 2004 | 1112 | 0.030 |
Why?
|
Early Detection of Cancer | 1 | 2010 | 3215 | 0.030 |
Why?
|
Kidney Diseases, Cystic | 1 | 1997 | 183 | 0.030 |
Why?
|
Workload | 1 | 2001 | 846 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2011 | 10434 | 0.030 |
Why?
|
Massachusetts | 1 | 2008 | 8805 | 0.030 |
Why?
|
Prevalence | 4 | 2015 | 15687 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2014 | 3774 | 0.030 |
Why?
|
Documentation | 1 | 2001 | 892 | 0.030 |
Why?
|
Laparotomy | 1 | 1997 | 468 | 0.030 |
Why?
|
Gene Library | 1 | 2017 | 1060 | 0.030 |
Why?
|
Tyrosine | 1 | 1999 | 1440 | 0.030 |
Why?
|
Soft Tissue Neoplasms | 1 | 2003 | 1151 | 0.030 |
Why?
|
Lymph Nodes | 2 | 2017 | 3491 | 0.030 |
Why?
|
Chromatin | 2 | 1998 | 2939 | 0.030 |
Why?
|
Prostatic Neoplasms | 2 | 1996 | 11341 | 0.030 |
Why?
|
Actomyosin | 1 | 2014 | 109 | 0.030 |
Why?
|
Hydrocephalus | 1 | 2000 | 763 | 0.030 |
Why?
|
Self-Examination | 1 | 2013 | 71 | 0.030 |
Why?
|
RNA, Viral | 1 | 2002 | 2837 | 0.030 |
Why?
|
Time-Lapse Imaging | 1 | 2014 | 192 | 0.030 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2014 | 235 | 0.030 |
Why?
|
Myosins | 1 | 2014 | 405 | 0.030 |
Why?
|
Hypothyroidism | 1 | 2018 | 665 | 0.030 |
Why?
|
Diploidy | 2 | 1991 | 132 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2015 | 597 | 0.030 |
Why?
|
United States | 3 | 2010 | 72363 | 0.030 |
Why?
|
Membrane Proteins | 3 | 2017 | 7854 | 0.030 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2005 | 2494 | 0.030 |
Why?
|
Glomerulonephritis | 1 | 1994 | 337 | 0.030 |
Why?
|
Coloring Agents | 1 | 2014 | 561 | 0.020 |
Why?
|
Pancreatitis | 1 | 1999 | 1100 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2016 | 1833 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2852 | 0.020 |
Why?
|
Breast Neoplasms | 4 | 2010 | 21065 | 0.020 |
Why?
|
Apoptosis | 1 | 2007 | 9497 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 2016 | 782 | 0.020 |
Why?
|
HIV Infections | 2 | 2016 | 17159 | 0.020 |
Why?
|
Goiter | 1 | 1991 | 87 | 0.020 |
Why?
|
Catheter Ablation | 1 | 2004 | 2755 | 0.020 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2014 | 568 | 0.020 |
Why?
|
Gene Rearrangement | 2 | 2008 | 1122 | 0.020 |
Why?
|
Cell Line, Tumor | 3 | 2014 | 16905 | 0.020 |
Why?
|
Ploidies | 1 | 1990 | 275 | 0.020 |
Why?
|
ras Proteins | 1 | 2015 | 1051 | 0.020 |
Why?
|
Markov Chains | 1 | 1993 | 971 | 0.020 |
Why?
|
Necrosis | 1 | 1994 | 1612 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2008 | 5324 | 0.020 |
Why?
|
Cytokinesis | 1 | 2011 | 172 | 0.020 |
Why?
|
Acetic Acid | 1 | 2009 | 60 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2508 | 0.020 |
Why?
|
Probability | 1 | 2015 | 2476 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2018 | 2007 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2015 | 2363 | 0.020 |
Why?
|
Incidental Findings | 1 | 2013 | 698 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2013 | 1181 | 0.020 |
Why?
|
Phenotype | 2 | 2017 | 16543 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2014 | 1972 | 0.020 |
Why?
|
Sex Distribution | 1 | 2013 | 2295 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 1991 | 749 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 1994 | 2220 | 0.020 |
Why?
|
Prostate | 1 | 1996 | 1793 | 0.020 |
Why?
|
Myosin Type II | 1 | 2007 | 70 | 0.020 |
Why?
|
Physical Examination | 1 | 2013 | 1244 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 1997 | 2696 | 0.020 |
Why?
|
Adherens Junctions | 1 | 2007 | 89 | 0.020 |
Why?
|
Down-Regulation | 1 | 2014 | 2918 | 0.020 |
Why?
|
Vacuoles | 1 | 1987 | 229 | 0.020 |
Why?
|
Software | 1 | 2001 | 4420 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4573 | 0.020 |
Why?
|
Cystadenoma | 1 | 1986 | 79 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 1996 | 2528 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1994 | 1378 | 0.020 |
Why?
|
Cell Division | 2 | 1991 | 4462 | 0.020 |
Why?
|
rho GTP-Binding Proteins | 1 | 2007 | 277 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8553 | 0.020 |
Why?
|
RNA Interference | 1 | 2014 | 2846 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 2473 | 0.020 |
Why?
|
Societies, Medical | 1 | 1998 | 3903 | 0.020 |
Why?
|
Carcinoembryonic Antigen | 1 | 1987 | 336 | 0.020 |
Why?
|
Gene Amplification | 1 | 2010 | 1085 | 0.020 |
Why?
|
Suppuration | 1 | 2005 | 61 | 0.020 |
Why?
|
Preoperative Care | 2 | 2004 | 2255 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2011 | 2056 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 3443 | 0.020 |
Why?
|
Leukemic Infiltration | 1 | 2005 | 47 | 0.020 |
Why?
|
Reoperation | 1 | 2015 | 4292 | 0.020 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 1986 | 296 | 0.020 |
Why?
|
Sinusitis | 1 | 1994 | 992 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 2007 | 1628 | 0.010 |
Why?
|
BCG Vaccine | 1 | 1987 | 371 | 0.010 |
Why?
|
Chromans | 1 | 2004 | 117 | 0.010 |
Why?
|
Aqueous Humor | 1 | 2005 | 154 | 0.010 |
Why?
|
History, 18th Century | 1 | 2004 | 207 | 0.010 |
Why?
|
Signal Transduction | 1 | 2007 | 23363 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1987 | 1705 | 0.010 |
Why?
|
Time Factors | 2 | 2013 | 40133 | 0.010 |
Why?
|
Medical Oncology | 1 | 1995 | 2321 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2011 | 2651 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2014 | 2978 | 0.010 |
Why?
|
Mucins | 1 | 1987 | 568 | 0.010 |
Why?
|
Sarcoma | 1 | 2014 | 1786 | 0.010 |
Why?
|
Pregnancy | 1 | 2005 | 29725 | 0.010 |
Why?
|
Double-Blind Method | 2 | 2012 | 12412 | 0.010 |
Why?
|
Models, Biological | 2 | 2011 | 9468 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 4494 | 0.010 |
Why?
|
India | 1 | 2009 | 2346 | 0.010 |
Why?
|
Lysosomes | 1 | 2007 | 919 | 0.010 |
Why?
|
Sampling Studies | 1 | 2003 | 614 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8621 | 0.010 |
Why?
|
Cell Lineage | 1 | 2011 | 2525 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2004 | 629 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6457 | 0.010 |
Why?
|
Thiazolidinediones | 1 | 2004 | 465 | 0.010 |
Why?
|
Benzamides | 1 | 2007 | 1369 | 0.010 |
Why?
|
Antigens | 1 | 1987 | 1447 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2007 | 3096 | 0.010 |
Why?
|
Urinary Bladder | 1 | 1987 | 1166 | 0.010 |
Why?
|
Bile Duct Neoplasms | 1 | 1986 | 600 | 0.010 |
Why?
|
Models, Genetic | 1 | 2011 | 3442 | 0.010 |
Why?
|
Genetic Testing | 1 | 2014 | 3530 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13505 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2018 | 11480 | 0.010 |
Why?
|
Tomography, Emission-Computed | 1 | 2003 | 1121 | 0.010 |
Why?
|
Actins | 1 | 2007 | 2049 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2007 | 1726 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2007 | 6131 | 0.010 |
Why?
|
Protein Kinases | 1 | 2007 | 1612 | 0.010 |
Why?
|
Sirolimus | 1 | 2007 | 1548 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2015 | 14482 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 3696 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2019 | 26168 | 0.010 |
Why?
|
Intraocular Pressure | 1 | 2005 | 1288 | 0.010 |
Why?
|
Risk Factors | 3 | 2004 | 74269 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2002 | 1900 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2007 | 2058 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 2005 | 2424 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2012 | 12762 | 0.010 |
Why?
|
Incidence | 1 | 2015 | 21378 | 0.010 |
Why?
|
Artifacts | 1 | 2005 | 1893 | 0.010 |
Why?
|
Cell Line | 1 | 2011 | 15626 | 0.010 |
Why?
|
Aging | 1 | 2015 | 8641 | 0.010 |
Why?
|
Herpesvirus 4, Human | 1 | 2002 | 1075 | 0.010 |
Why?
|
Piperazines | 1 | 2007 | 2520 | 0.010 |
Why?
|
Ultrasonography, Interventional | 1 | 2004 | 1503 | 0.010 |
Why?
|
Hypertension | 1 | 2016 | 8595 | 0.010 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 1999 | 505 | 0.010 |
Why?
|
Automation | 1 | 1998 | 581 | 0.010 |
Why?
|
Glaucoma | 1 | 2005 | 1183 | 0.010 |
Why?
|
Pyrimidines | 1 | 2007 | 3011 | 0.010 |
Why?
|
Freezing | 1 | 1995 | 306 | 0.010 |
Why?
|
Centromere | 1 | 1995 | 213 | 0.010 |
Why?
|
Peripheral Nervous System Neoplasms | 1 | 1995 | 125 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 2002 | 2696 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2007 | 4168 | 0.010 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1995 | 534 | 0.010 |
Why?
|
Models, Structural | 1 | 1993 | 341 | 0.010 |
Why?
|
Genetic Techniques | 1 | 1995 | 428 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2007 | 5230 | 0.010 |
Why?
|
Organ Transplantation | 1 | 2002 | 1150 | 0.010 |
Why?
|
Algorithms | 1 | 2012 | 13967 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 1991 | 6855 | 0.010 |
Why?
|
Gene Dosage | 1 | 1995 | 1218 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2007 | 5640 | 0.010 |
Why?
|
S Phase | 1 | 1991 | 422 | 0.010 |
Why?
|
Animals | 1 | 2000 | 167940 | 0.000 |
Why?
|
Clinical Laboratory Techniques | 1 | 1994 | 749 | 0.000 |
Why?
|
Reference Values | 1 | 1995 | 4920 | 0.000 |
Why?
|
Gene Deletion | 1 | 1995 | 2668 | 0.000 |
Why?
|
Administration, Intravesical | 1 | 1987 | 92 | 0.000 |
Why?
|
Stents | 1 | 1999 | 3303 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2003 | 22041 | 0.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 11708 | 0.000 |
Why?
|
Logistic Models | 1 | 1998 | 13311 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 1999 | 9196 | 0.000 |
Why?
|
Cell Separation | 1 | 1987 | 1720 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 2004 | 13629 | 0.000 |
Why?
|
Pancreatic Neoplasms | 1 | 1999 | 5333 | 0.000 |
Why?
|
Survival Analysis | 1 | 1991 | 10185 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1987 | 8551 | 0.000 |
Why?
|
Liver | 1 | 1986 | 7512 | 0.000 |
Why?
|